+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Europe Heparin Market to Reach US$3.1 bn by 2022 due to High Incidence of Thrombosis

Posted on Feb 19, 2016

Heparin is one of the most widely used injectable blood thinners. Its increasing application in the treatment and prevention of deep vein thrombosis, pulmonary embolism, unstable angina, and myocardial infarction has augmented the demand from the heparin market. In its report, titled “Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022,” Transparency Market Research (TMR) provides insights into the factors influencing the Europe heparin market and its growth trajectory.

Browse the full Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at http://www.transparencymarketresearch.com/europe-heparin-market.html

Based on an in-depth survey conducted in order to provide comprehensive data, the report pegs the overall value of the Europe heparin market at just over US$2 bn in 2013. Rising at a CAGR of 5.2%, the market is expected to reach US$3.1 bn by the end of 2022.

According to the National Health Service (NHS), one in every three patients who undergo knee or hip replacements without thrombophylaxis is likely to develop asymptomatic DVT, while one in every 30 people may suffer from symptomatic VTE. Influenced by such rising prevalence of thrombosis, hospitals and healthcare institutions across the U.K. are increasingly demanding heparin. Additionally, a new operating framework recently published by the chief medical officer in the Department of Health in the U.K. mandates hospitals to conduct risk assessment for thrombosis in at least 90% of patients admitted to hospitals. Such stringent regulations will boost the market for heparin in European countries such as Italy, Spain, and the U.K.

To present a holistic overview, the report segments the Europe heparin market based on product type and country. Based on product, the Europe heparin market comprises ultra-low molecular weight heparin (ULMWH), low-molecular weight heparin (LMWH), and unfractionated heparin. Among these, the demand for unfractionated heparin majorly arises from hospitals for application in dialysis and the treatment of thrombotic disorders. However, low application areas and bleeding disorders are among the key factors restraining the market for unfractionated heparin in Europe,

LMWHs, however, witness high demand, since they are used during the treatment of diseases such as venous thromboembolism and various other surgical procedures. The demand for LMWHs is therefore anticipated to increase substantially in forthcoming years. Besides, the majority of research and development initiatives conducted in Europe are aimed at comparing the activities of LMWHs with ULMWHs in cancer and neurological disorders. The Europe heparin market will be significantly benefited if the findings from the research receive approval in the market.

Geographically, the report segments the Europe heparin market into EU5 countries including France, Spain, Italy, Germany, the U.K., and Rest of the Europe. In 2013, Germany accounted for the largest share in the Europe heparin market due to high demand for unfractionated heparin and LMWHs. Apart from Germany, France is also a leading market for unfractionated heparin.

The report segments the Europe Heparin Market as:

Europe Heparin Market, by Product

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWHs)
  • Ultra-low Molecular Weight Heparin (ULMWHs)

Europe Heparin Market, by Country

  • United Kingdom
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Germany
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • France
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Spain
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Italy
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)
  • Rest of the Europe
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (LMWHs)
    • Ultra-low Molecular Weight Heparin (ULMWHs)

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Back To Top